Zacks: Analysts Anticipate Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Will Post Quarterly Sales of $5.65 Million

Analysts expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to report sales of $5.65 million for the current quarter, Zacks reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $6.00 million and the lowest estimate coming in at $5.00 million. Syros Pharmaceuticals posted sales of $5.70 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 0.9%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 3rd.

According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $21.32 million for the current fiscal year, with estimates ranging from $20.69 million to $21.69 million. For the next financial year, analysts anticipate that the business will post sales of $17.79 million, with estimates ranging from $8.40 million to $21.40 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Syros Pharmaceuticals.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Friday, November 5th. The company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.03. Syros Pharmaceuticals had a negative return on equity of 77.65% and a negative net margin of 434.32%. During the same quarter last year, the business earned ($0.43) earnings per share.

Several research analysts have recently commented on SYRS shares. Zacks Investment Research raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 10th. Roth Capital upped their target price on Syros Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, September 23rd. JMP Securities reaffirmed a “buy” rating and issued a $20.00 target price on shares of Syros Pharmaceuticals in a research note on Tuesday, September 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, November 8th.

Hedge funds have recently made changes to their positions in the business. Trexquant Investment LP lifted its position in Syros Pharmaceuticals by 97.8% in the second quarter. Trexquant Investment LP now owns 33,676 shares of the company’s stock valued at $184,000 after purchasing an additional 16,650 shares during the last quarter. Altium Capital Management LP lifted its position in Syros Pharmaceuticals by 750.0% in the second quarter. Altium Capital Management LP now owns 1,076,942 shares of the company’s stock valued at $5,869,000 after purchasing an additional 950,240 shares during the last quarter. Cubist Systematic Strategies LLC lifted its position in Syros Pharmaceuticals by 891.3% in the second quarter. Cubist Systematic Strategies LLC now owns 257,997 shares of the company’s stock valued at $1,406,000 after purchasing an additional 231,972 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Syros Pharmaceuticals by 47.4% in the second quarter. Virtus ETF Advisers LLC now owns 37,977 shares of the company’s stock valued at $207,000 after purchasing an additional 12,204 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Syros Pharmaceuticals by 16.0% in the second quarter. Geode Capital Management LLC now owns 966,448 shares of the company’s stock valued at $5,267,000 after purchasing an additional 133,440 shares during the last quarter. Hedge funds and other institutional investors own 82.18% of the company’s stock.

Shares of NASDAQ SYRS traded up $0.08 during midday trading on Thursday, hitting $4.13. 408,990 shares of the company’s stock were exchanged, compared to its average volume of 830,844. Syros Pharmaceuticals has a 12-month low of $3.70 and a 12-month high of $15.65. The company has a current ratio of 5.13, a quick ratio of 6.74 and a debt-to-equity ratio of 0.38. The company has a market cap of $255.84 million, a price-to-earnings ratio of -2.55 and a beta of 1.85. The business’s fifty day moving average price is $4.40 and its two-hundred day moving average price is $4.93.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Recommended Story: Market Perform

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.